Blockchain Registration Transaction Record

B2i Digital Showcases Lakewood-Amedex's Novel Antimicrobial Class

B2i Digital partners with Lakewood-Amedex to promote Nu-3, a novel antimicrobial gel for infected diabetic foot ulcers, with Phase 2a trial underway. Learn about the Bisphosphocin class.

This news matters because antimicrobial resistance is a growing global health crisis, rendering many existing antibiotics ineffective. Lakewood-Amedex's Bisphosphocin® class offers a novel mechanism that could combat resistant infections like MRSA, which are particularly dangerous in diabetic foot ulcers. The upcoming Phase 2a trial will provide crucial data on safety and efficacy, potentially leading to a new treatment option for a condition that affects millions and often results in amputation. For investors, this represents an early opportunity to engage with a promising clinical-stage company addressing an unmet medical need.